中文名 | JD-5037 |
英文名 | (S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide |
别名 | 化合物JD5037 |
英文别名 | JD 5037 JD-5037 CS-2558 (S)-2-((Z)-(((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(4-chlorophenylsulfonamido)methylene)amino)-3-methylbutanamide (S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide Butanamide, 2-[[[(4S)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazol-1-yl][[(4-chlorophenyl)sulfonyl]amino]methylene]amino]-3-methyl-, (2S)- |
CAS | 1392116-14-1 |
化学式 | C27H27Cl2N5O3S |
分子量 | 572.51 |
密度 | 1.40±0.1 g/cm3(Predicted) |
沸点 | 721.6±70.0 °C(Predicted) |
溶解度 | DMSO |
酸度系数 | 10.63±0.60(Predicted) |
存储条件 | 2-8℃ |
MDL号 | MFCD30533451 |
靶点 | CB1 |
体内研究 | JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice. |
参考资料 展开查看 | 1. Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4751-60.2. Knani I, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 2016 Oct 22;5(12):1187-1199.3. Mukhopadhyay B, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 2015 May;61(5):1615-26. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.747 ml | 8.733 ml | 17.467 ml |
5 mM | 0.349 ml | 1.747 ml | 3.493 ml |
10 mM | 0.175 ml | 0.873 ml | 1.747 ml |
5 mM | 0.035 ml | 0.175 ml | 0.349 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!